CoChat
Sign Up
Cited by 867Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Bolinder, Jan, Ljunggren, Östen, Kullberg, Joel, Johansson, Lars, Wilding, John, Langkilde, Anna Maria, Sugg, Jennifer, Parikh, Shamik·2012·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2011-2260
Open this paper in CoChat — free account

Abstract

CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2011-2260

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

  1. Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21

Cited by

Sorted by citations

Items 701–800 of 864

Related

See all

Metadata

Authors
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
Affiliations
  • Karolinska University Hospital (SE)
  • Uppsala University Hospital (SE)
  • Aintree University Hospital (GB)
  • AstraZeneca (Sweden) (SE)
  • AstraZeneca (United States) (US)
Corresponding author
Bolinder, Jan
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2012-03-01
Volume
97
Issue
3
Pages
1020-1031
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2011-2260
OpenAlex
W2167245776
Cited by
867
References
36
Citations by year
2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
FWCI
48.94
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
MeSH terms
Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review